Dirk Witters
Direktor/Vorstandsmitglied bei IMMUNOPRECISE ANTIBODIES LTD.
Vermögen: 2 328 $ am 30.04.2024
Profil
Dirk Witters has held director positions at ImmunoPrecise Antibodies Ltd.
and BioStrand BV.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.01.2024 | 1 950 ( 0,01% ) | 2 328 $ | 30.04.2024 |
Aktive Positionen von Dirk Witters
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Direktor/Vorstandsmitglied | 05.09.2023 |
BioStrand BV
 BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BioStrand BV
BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Commercial Services |
